Raiffeisen Bank International AG Invests $29,000 in Repligen Co. (NASDAQ:RGEN)

Raiffeisen Bank International AG purchased a new position in Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200 shares of the biotechnology company’s stock, valued at approximately $29,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Ballentine Partners LLC lifted its stake in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after buying an additional 72 shares in the last quarter. CIBC Asset Management Inc lifted its stake in shares of Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after buying an additional 81 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after buying an additional 100 shares in the last quarter. Utah Retirement Systems lifted its stake in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 100 shares in the last quarter. Finally, Peapack Gladstone Financial Corp lifted its stake in shares of Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company’s stock worth $301,000 after buying an additional 103 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of RGEN opened at $126.19 on Tuesday. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The stock has a market cap of $7.09 billion, a PE ratio of -247.43, a P/E/G ratio of 4.54 and a beta of 1.21. The firm has a 50-day simple moving average of $132.36 and a two-hundred day simple moving average of $145.11. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same period last year, the business earned $0.28 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on RGEN shares. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. Royal Bank of Canada reduced their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Finally, Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $173.25.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.